GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » Beta

AMEUF (Anteris Technologies) Beta : -0.19 (As of Dec. 15, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Anteris Technologies Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-15), Anteris Technologies's Beta is -0.19.


Anteris Technologies Beta Historical Data

The historical data trend for Anteris Technologies's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anteris Technologies Beta Chart

Anteris Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.22 2.33 2.71 1.99 0.21

Anteris Technologies Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.77 1.99 0.10 0.21 0.04

Competitive Comparison of Anteris Technologies's Beta

For the Medical Devices subindustry, Anteris Technologies's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anteris Technologies's Beta Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies's Beta distribution charts can be found below:

* The bar in red indicates where Anteris Technologies's Beta falls into.



Anteris Technologies Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Anteris Technologies  (OTCPK:AMEUF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Anteris Technologies Beta Related Terms

Thank you for viewing the detailed overview of Anteris Technologies's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Anteris Technologies Business Description

Traded in Other Exchanges
Address
9 Sherwood Road, Level 3, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris' DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. It is also engaged in research and development of ComASUR, a delivery system that allows accurate valve placement, and the manufacturing and selling of proprietary ADAPT regenerative tissue products. The company generates a majority of its revenue from the United States and the rest from Switzerland and Australia.